Jamieson Bondarenko, a Director and 10% Holder, acquired 2,142,900 Common Shares on a direct ownership basis at a price of $0.070 through a prospectus or prospectus exempt offering on October 15th, 2019. This represents a $150,003 investment into the company's shares and an account share holdings change of 6.3%.
William Williams, CEO and Director, acquired 2,142,857 Common Shares on a direct ownership basis at a price of $0.070 through a private transaction on October 15th, 2019. This represents a $150,000 investment into the company's shares and an account share holdings change of 11.9%.
Vaughn Embro-Pantalony, a Director, acquired 1,428,571 Common Shares on a direct ownership basis at a price of $0.070 through a private transaction on October 15th, 2019. This represents a $100,000 investment into the company's shares and an account share holdings change of 100.0%.
BriaCell Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
BriaCell Therapeutics Corp. is a Canada-based immuno-oncology biotechnology company, which develops treatments for cancer. Its lead product candidate, Bria-IMT, is being tested in a clinical trial in combination with pembrolizumab in patients with advanced breast cancer. The Company also is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer patients, and BriaDX, its companion diagnostic test. The Company's preclinical small molecule program consists of protein kinase C delta inhibitors for cancer and fibrotic diseases.
No Comments